Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.76 Million SEK | 88.7% |
| 2022 | -24.45 Million SEK | -18.18% |
| 2021 | -20.69 Million SEK | -10.07% |
| 2020 | -18.8 Million SEK | -446.99% |
| 2019 | -3.43 Million SEK | 84.54% |
| 2018 | -22.23 Million SEK | -186.48% |
| 2017 | -7.76 Million SEK | -782.82% |
| 2016 | -879 Thousand SEK | -132.54% |
| 2015 | -378 Thousand SEK | 58.14% |
| 2014 | -902.92 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -17 Million SEK | -515.49% |
| 2024 Q2 | -21.68 Million SEK | -27.52% |
| 2023 FY | -2.76 Million SEK | 88.7% |
| 2023 Q1 | -14.98 Million SEK | 38.74% |
| 2023 Q2 | -12.46 Million SEK | 16.8% |
| 2023 Q4 | -2.76 Million SEK | 63.27% |
| 2023 Q3 | -7.52 Million SEK | 39.66% |
| 2022 Q2 | -15.8 Million SEK | -6.91% |
| 2022 Q4 | -24.45 Million SEK | -184.52% |
| 2022 Q1 | -14.78 Million SEK | 28.57% |
| 2022 FY | -24.45 Million SEK | -18.18% |
| 2022 Q3 | -8.59 Million SEK | 45.61% |
| 2021 Q1 | -17.35 Million SEK | 7.68% |
| 2021 FY | -20.69 Million SEK | -10.07% |
| 2021 Q4 | -20.69 Million SEK | -304.26% |
| 2021 Q3 | -5.11 Million SEK | 50.08% |
| 2021 Q2 | -10.25 Million SEK | 40.92% |
| 2020 Q4 | -18.8 Million SEK | 5.05% |
| 2020 Q1 | -4.06 Million SEK | -18.18% |
| 2020 Q2 | -413 Thousand SEK | 89.83% |
| 2020 Q3 | -19.8 Million SEK | -4694.19% |
| 2020 FY | -18.8 Million SEK | -446.99% |
| 2019 Q1 | -16.87 Million SEK | 24.1% |
| 2019 FY | -3.43 Million SEK | 84.54% |
| 2019 Q4 | -3.43 Million SEK | 60.57% |
| 2019 Q3 | -8.71 Million SEK | 32.15% |
| 2019 Q2 | -12.84 Million SEK | 23.87% |
| 2018 Q3 | -26.29 Million SEK | 12.16% |
| 2018 FY | -22.23 Million SEK | -186.48% |
| 2018 Q2 | -29.92 Million SEK | -497.98% |
| 2018 Q1 | -5 Million SEK | 35.5% |
| 2018 Q4 | -22.23 Million SEK | 15.44% |
| 2017 Q1 | 1.09 Million SEK | 225.18% |
| 2017 Q4 | -7.76 Million SEK | 0.0% |
| 2017 FY | -7.76 Million SEK | -782.82% |
| 2016 FY | -879 Thousand SEK | -132.54% |
| 2016 Q4 | -877.95 Thousand SEK | 0.0% |
| 2015 FY | -378 Thousand SEK | 58.14% |
| 2014 FY | -902.92 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 94.476% |
| Ziccum AB (publ) | -2.13 Million SEK | -29.293% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 85.504% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.545% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 94.467% |
| Mendus AB (publ) | -96.29 Million SEK | 97.131% |
| Genovis AB (publ.) | -43.94 Million SEK | 93.712% |
| Intervacc AB (publ) | -88.16 Million SEK | 96.866% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 113.471% |
| Active Biotech AB (publ) | -33.2 Million SEK | 91.678% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 105.191% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 92.984% |
| Aptahem AB (publ) | 2.9 Million SEK | 194.993% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 99.172% |
| Kancera AB (publ) | -45.69 Million SEK | 93.953% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 99.16% |
| Saniona AB (publ) | 40.44 Million SEK | 106.831% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 91.346% |
| Biovica International AB (publ) | -58.73 Million SEK | 95.296% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 93.889% |
| AcouSort AB (publ) | -23.98 Million SEK | 88.481% |
| Xintela AB (publ) | -7.8 Million SEK | 64.618% |
| Abliva AB (publ) | -57.24 Million SEK | 95.173% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 98.581% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 96.639% |
| OncoZenge AB (publ) | -12.62 Million SEK | 78.118% |
| Amniotics AB (publ) | -5.63 Million SEK | 50.941% |
| 2cureX AB (publ) | -13.4 Million SEK | 79.385% |
| CombiGene AB (publ) | -101.44 Million SEK | 97.276% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -27.857% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 151.167% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.763% |
| Corline Biomedical AB | -17.01 Million SEK | 83.759% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 96.701% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 98.0% |
| I-Tech AB | -83.26 Million SEK | 96.682% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 102.051% |
| Cyxone AB (publ) | -16.67 Million SEK | 83.425% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 95.056% |
| Biosergen AB | -1.88 Million SEK | -46.734% |
| Cantargia AB (publ) | -139.74 Million SEK | 98.023% |
| NextCell Pharma AB | -46.79 Million SEK | 94.095% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 97.866% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 90.597% |
| Nanologica AB (publ) | -9.38 Million SEK | 70.569% |
| SynAct Pharma AB | -61.75 Million SEK | 95.526% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 87.098% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 79.114% |
| LIDDS AB (publ) | -13.51 Million SEK | 79.552% |
| Lipum AB (publ) | -8.46 Million SEK | 67.36% |
| BioInvent International AB (publ) | -236.3 Million SEK | 98.831% |
| Alzinova AB (publ) | -21.22 Million SEK | 86.983% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 95.871% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 46.67% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 96.701% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -199.35% |
| Simris Alg AB (publ) | 85.07 Million SEK | 103.248% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 96.634% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 101.664% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 86.712% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 7.032% |